Cancer Research UK Science and Innovation’s Post

EGFR mutations are one of the most common causes of #NSCLC tumors. Dive into the CHRYSALIS study with our informative infographic, which is evaluating amivantamab treatment for NSCLC patients with EGFR mutations: https://bit.ly/40sCWhj @Future_OncolFSG

🎧 In this week's episode of the #EADVPodcast we cover the JEADV Editor's Picks for January 2024, including: 📌Treatment with antineoplastic potential in squamous cell #carcinoma 📌 Penile #cancer carcinogenesis and the role of #HPV 📌 Sensitive Skin - neuropathic in nature? 📌 Urgency of optimal imaging in toxic epidermal necrolysis >>

NSCLC tumors with EGFR mutations are difficult to treat or do not experience treatment response with commonly used therapies that target EGFR. Data from the CHRYSALIS study suggests that amivantamab may hold promise in #NSCLC treatment for EGFR exon 20 insertion mutation patients. Discover further details here: https://bit.ly/466udCr

Instructions are below  Mitomap.org (this is one of the references I have to use

Novel Drug Delivery Systems In Cancer Therapy Market  The Novel Drug Delivery Systems In Cancer Therapy Market Size is valued at 10.45 Billion in 2022 and is predicted to reach 62.44 Billion by the year 2031 at a 22.25 % CAGR during the forecast period for 2023-2031. Get Free Request Sample:https://lnkd.in/gJvd7xRi Read Press Release: https://lnkd.in/dFbB5jDW #novel #drug #delivery #systems #cancer #therapy #marketresearch #marketresearchreport

 Adapted from the peer-reviewed paper 10.3390/molecules28155905

Invion's Exec Chair and CEO, Thian Chew, explains the significance of the recent pre-clincal results undertaken by the Peter MacCallum Cancer Centre showing how dramatically INV043 can improve immune checkpoint inhibitor (ICI) therapies in this short 3min plus video. #cancerresearch #stockstowatch #biotech #cancertreatment #asx https://lnkd.in/gN4bw-Zg

🎗 Chest Cancer Detection Using CNNs! ✨ Thrilled to share my work on leveraging Convolutional Neural Networks (CNNs) for chest CT-scan classification! ➡ This project tackles the challenge of early chest cancer detection by training a CNN model to distinguish between four key classes: squamous cell carcinoma, normal, adenocarcinoma, and large cell carcinoma. By automating some aspects of CT-scan analysis, CNNs have the potential to improve accuracy, efficiency, and ultimately, patient outcomes in the fight against cancer. https://lnkd.in/e6u8v44r #Healthcare #AI #MachineLearning #ChestXray #CancerDetection

Top downloaded article in 2023!

One of the great things about taking some time out to focus on personal development is the flexibility to get involved in things that I care about, like collecting for the Breast Cancer Foundation NZ If you have a couple of hours that you can spare on the 27th or 28th October, click on the link below to find a shift.